# Post Marketing Surveillance Study of Biphasic Insulin Aspart 30

> **NCT01536613** · — · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 5346 (actual)

## Conditions studied

- Diabetes
- Diabetes Mellitus, Type 1
- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** biphasic insulin aspart 30

## Key facts

- **NCT ID:** NCT01536613
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2004-09
- **Primary completion:** 2007-02
- **Final completion:** 2007-02
- **Target enrollment:** 5346 (ACTUAL)
- **Last updated:** 2016-03-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01536613

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01536613, "Post Marketing Surveillance Study of Biphasic Insulin Aspart 30". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT01536613. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*